查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2040396

日光性角化症治療市場規模、佔有率和趨勢分析報告：按治療方法、藥物類別、應用、地區和細分市場分類（2026-2033 年）

Actinic Keratosis Treatment Market Size, Share & Trends Analysis Report By Therapy, By Drug Class, By End Use, By Region, And Segment Forecasts, 2026 - 2033
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

日光性角化症治療市場概覽

據估計，2025 年全球日光性角化病治療市場價值為 70.2 億美元，預計到 2033 年將達到 101.3 億美元，2026 年至 2033 年的複合年成長率為 4.86%。

由於長期暴露於紫外線 (UV) 輻射，導致日光性角化病日益普遍，以及老年人口不斷成長，老年人更容易受到陽光引起的皮膚損傷，從而推動了這一成長。

人們對早期診斷癌前皮膚病重要性的認知不斷提高，以及皮膚科醫療服務的可近性改善，也推動了市場擴張。此外，局部治療、動態療法 (PDT) 技術和冷凍療法的進步，以及有效處方藥的普及，也進一步促進了市場的穩定成長。

日光性角化症是最常見的皮膚癌前病變之一，主要由長期暴露於陽光和人造光源的紫外線 (UV) 引起。其發病率不斷上升，尤其是在膚色較淺的人群和老年人中，顯著擴大了需要治療的患者群體。例如，2024 年 4 月，牛津大學出版社在《英國皮膚病學雜誌》上發表了Meta分析，報告稱全球整體日光性角化病的患病率為 14%（95% 置信區間：14-15%），熱帶和溫帶地區的患病率高達 18%，60 歲以上人群的患病率高達 19%。這種日益加重的疾病負擔直接導致對有效治療性介入的需求不斷成長。

此外，民眾對皮膚疾病的認知不斷提高，早期診斷技術不斷進步，再加上大規模公共衛生舉措和篩檢計畫的支持，也推動了市場成長。各國政府和皮膚​​科組織都在積極推廣皮膚病變的早期檢測，並鼓勵人們及時就醫。例如，2024年5月，皮膚癌基金會報告稱，美國每年新增皮膚癌病例超過500萬例，五分之一的人在70歲前會罹患皮膚癌。這主要與紫外線照射有關。此外，篩檢活動已被證明在早期發現方面行之有效。 2024年，美國皮膚病學會報告稱，其透過相關項目篩檢了超過290萬人，並發現了超過29.3萬例疑似病變。這些努力極大地促進了日光性角化症的早期診斷和治療，從而推動了市場成長。

目錄

第1章 日光性角化症治療市場：調查方法與範圍

第2章 日光性角化症治療市場：執行摘要

  • 市場概覽
  • 治療概述
  • 藥物類別概述
  • 最終用途概述
  • 競爭格局概述

第3章 日光性角化症治療市場：變數、趨勢與範圍

  • 市場區隔和範圍
  • 市場譜系展望
  • 市場動態
  • 市場動態分析
  • 市場限制因素分析
  • 波特五力分析
  • PESTEL 分析
  • 管道分析

第4章 日光性角化症治療市場：依治療方法進行估計與趨勢分析

  • 全球光化性角化症治療市場：治療方法概覽
  • 全球日光性角化症治療市場：依治療方法分類的波動分析
  • 全球日光性角化症治療市場：依治療方法及銷售收入分類
  • 外用
  • 外科手術
  • 動態療法

第5章：日光性角化症治療市場：依藥物類別分類的估計與趨勢分析

  • 全球光化性角化症治療市場：藥物類別概覽
  • 全球光化性角化症治療市場：按藥物類別分類的波動分析
  • 全球日光性角化症治療市場：依藥物類別及銷售收入分類
  • 核苷代謝抑制劑
  • NSAIDs
  • 免疫療法調節劑
  • 光敏劑
  • 其他

第6章 日光性角化症治療市場：依最終用途分類的估計與趨勢分析

  • 全球日光性角化症治療市場：依最終用途分類的概覽
  • 全球日光性角化症治療市場：依最終用途分類的波動分析
  • 全球日光性角化症治療市場：依最終用途及銷售收入分類
  • 醫院
  • 私人診所
  • 居家醫療
  • 其他

第7章 日光性角化症治療市場：區域估計與趨勢分析

  • 區域儀錶板
  • 市場規模、預測與趨勢分析，2021-2033年
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 挪威
    • 瑞典
    • 丹麥
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 泰國
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第8章 競爭情勢

  • 主要市場參與企業近期趨勢及影響分析
  • 公司和競爭對手的分類
  • 供應商情況
    • 主要銷售代理商和通路夥伴名單
    • 主要公司市佔率分析（2025 年）
    • Almirall, SA
    • Brymill Cryogenic Systems
    • Sun Pharmaceutical Industries Ltd.
    • Cortex Technology
    • Galderma
    • Ortho Dermatologics（Bausch Health Companies Inc.）
    • BIOFRONTERA Inc.
    • Hill Dermaceuticals, Inc
    • Teva Pharmaceutical
    • Viatris Inc.
Product Code: GVR-2-68038-940-1

Actinic Keratosis Treatment Market Summary

The global actinic keratosis treatment market size was estimated at USD 7.02 billion in 2025 and is projected to reach USD 10.13 billion by 2033, growing at a CAGR of 4.86% from 2026 to 2033. This growth is driven by the increasing prevalence of actinic keratosis due to prolonged ultraviolet (UV) exposure and a growing aging population vulnerable to sun-related skin damage.

Rising awareness about early diagnosis of precancerous skin conditions and improved access to dermatology services are also supporting market expansion. In addition, advancements in topical therapies, photodynamic therapy technologies, and cryotherapy procedures, along with the availability of effective prescription medications, are further contributing to the market's steady growth.

Actinic keratosis is among the most common precancerous skin conditions, largely caused by prolonged exposure to ultraviolet (UV) radiation from sunlight or artificial sources. The increasing incidence, particularly among fair-skinned and aging populations, is significantly expanding the patient pool requiring treatment. For instance, in April 2024, Oxford University Press published a meta-analysis in the British Journal of Dermatology reporting a pooled global prevalence of 14% (95% CI: 14-15), with rates reaching 18% in tropical and temperate regions and 19% among individuals aged over 60 years. This growing disease burden is directly translating into higher demand for effective therapeutic interventions.

The market is also benefiting from increasing awareness and early diagnosis of skin disorders, supported by large-scale public health initiatives and screening programs. Governments and dermatology organizations are actively promoting early detection of skin lesions, encouraging individuals to seek timely medical consultation. For instance, in May 2024, the Skin Cancer Foundation reported that over 5 million skin cancer cases are diagnosed annually in the U.S., with 1 in 5 individuals expected to develop skin cancer by age 70, largely linked to UV exposure. Additionally, screening initiatives have proven effective in early identification; the American Academy of Dermatology reported in 2024 that its programs have screened over 2.9 million individuals, identifying more than 293,000 suspicious lesions. Such initiatives are significantly contributing to earlier diagnosis and treatment of actinic keratosis, thereby driving market growth.

Global Actinic Keratosis Treatment Market Report Segmentation

This report forecasts revenue growth and provides an analysis on the latest trends in each of the sub-segments from 2021 to 2033. For this report, Grand View Research has segmented the actinic keratosis treatment market on the basis of therapy, drug class, end use, and region:

  • Therapy Outlook (USD Million, 2021 - 2033)
  • Topical
  • Surgery
  • Photodynamic Therapy
  • Drug Class Outlook (USD Million; 2021 - 2033)
  • Nucleoside Metabolic Inhibitor
  • NSAIDs
  • Immune Response Modifiers
  • Photoenhancers
  • Others
  • End Use Outlook (USD Million,2021 - 2033)
  • Hospitals
  • Private Clinics
  • Homecare
  • Others
  • Regional Outlook (Revenue, USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East and Africa (MEA)
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Actinic Keratosis Treatment Market: Methodology and Scope

  • 1.1. Market Segmentation and Scope
    • 1.1.1. Segment Definitions
      • 1.1.1.1. Product Method
      • 1.1.1.2. Drug Class Segment
      • 1.1.1.3. End Use Segment
  • 1.2. Regional Scope
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Objectives
    • 1.4.1. Objective - 1
    • 1.4.2. Objective - 2
    • 1.4.3. Objective - 3
  • 1.5. Research Methodology
  • 1.6. Information Procurement
    • 1.6.1. Purchased Database
    • 1.6.2. GVR's Internal Database
    • 1.6.3. Secondary Sources
    • 1.6.4. Primary Research
  • 1.7. Information or Data Analysis
    • 1.7.1. Data Analysis Models
  • 1.8. Market Formulation & Validation
  • 1.9. Model Details
    • 1.9.1. Commodity Flow Analysis
  • 1.10. List of Secondary Sources
  • 1.11. List of Abbreviations

Chapter 2. Actinic Keratosis Treatment Market: Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Therapy Snapshot
  • 2.3. Drug Class Snapshot
  • 2.4. End Use Snapshot
  • 2.5. Competitive Landscape Snapshot

Chapter 3. Actinic Keratosis Treatment Market Variables, Trends, & Scope

  • 3.1. Market Segmentation and Scope
  • 3.2. Market Lineage Outlook
    • 3.2.1. Parent Market Outlook
    • 3.2.2. Related/Ancillary Market Outlook
  • 3.3. Market Dynamics
  • 3.4. Market Drivers Analysis
  • 3.5. Market Restraint Analysis
  • 3.6. Porter's Five Forces Analysis
  • 3.7. PESTLE Analysis
  • 3.8. Pipeline Analysis

Chapter 4. Actinic Keratosis Treatment Market: Therapy Estimates & Trend Analysis

  • 4.1. Global Actinic Keratosis Treatment Market: Therapy Dashboard
  • 4.2. Global Actinic Keratosis Treatment Market: Therapy Movement Analysis
  • 4.3. Global Actinic Keratosis Treatment Market by therapy, Revenue
  • 4.4. Topical
    • 4.4.1. Topical market estimates and forecasts 2021 to 2033 (USD Million)
  • 4.5. Surgery
    • 4.5.1. Surgery market estimates and forecasts 2021 to 2033 (USD Million)
  • 4.6. Photodynamic Therapy
    • 4.6.1. Photodynamic Therapy market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 5. Actinic Keratosis Treatment Market: Drug Class Estimates & Trend Analysis

  • 5.1. Global Actinic Keratosis Treatment Market: Drug Class Dashboard
  • 5.2. Global Actinic Keratosis Treatment Market: Drug Class Movement Analysis
  • 5.3. Global Actinic Keratosis Treatment Market by Drug Class, Revenue
  • 5.4. Nucleoside Metabolic Inhibitor
    • 5.4.1. Nucleoside Metabolic Inhibitor market estimates and forecasts 2021 to 2033 (USD Million)
  • 5.5. NSAIDs
    • 5.5.1. NSAIDs market estimates and forecasts 2021 to 2033 (USD Million)
  • 5.6. Immune Response Modifiers
    • 5.6.1. Immune Response Modifiers market estimates and forecasts 2021 to 2033 (USD Million)
  • 5.7. Photoenhancers
    • 5.7.1. Photoenhancers market estimates and forecasts 2021 to 2033 (USD Million)
  • 5.8. Others
    • 5.8.1. Others market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 6. Actinic Keratosis Treatment Market: End Use Estimates & Trend Analysis

  • 6.1. Global Actinic Keratosis Treatment Market: End Use Dashboard
  • 6.2. Global Actinic Keratosis Treatment Market: End Use Movement Analysis
  • 6.3. Global Actinic Keratosis Treatment Market by End Use, Revenue
  • 6.4. Hospitals
    • 6.4.1. Diagnostic laboratories market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.5. Private Clinics
    • 6.5.1. Private Clinics market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.6. Homecare
    • 6.6.1. Homecare market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.7. Others
    • 6.7.1. Others market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 7. Actinic Keratosis Treatment Market: Regional Estimates & Trend Analysis by Product Type, Technology, and End Use

  • 7.1. Regional Dashboard
  • 7.2. Market Size, & Forecasts Trend Analysis, 2021 to 2033:
  • 7.3. North America
    • 7.3.1. U.S.
      • 7.3.1.1. Key country dynamics
      • 7.3.1.2. Regulatory framework/ reimbursement structure
      • 7.3.1.3. Competitive scenario
      • 7.3.1.4. U.S. market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.3.2. Canada
      • 7.3.2.1. Key country dynamics
      • 7.3.2.2. Regulatory framework/ reimbursement structure
      • 7.3.2.3. Competitive scenario
      • 7.3.2.4. Canada market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.3.3. Mexico
      • 7.3.3.1. Key country dynamics
      • 7.3.3.2. Regulatory framework/ reimbursement structure
      • 7.3.3.3. Competitive scenario
      • 7.3.3.4. Mexico market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.4. Europe
    • 7.4.1. UK
      • 7.4.1.1. Key country dynamics
      • 7.4.1.2. Regulatory framework/ reimbursement structure
      • 7.4.1.3. Competitive scenario
      • 7.4.1.4. UK market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.4.2. Germany
      • 7.4.2.1. Key country dynamics
      • 7.4.2.2. Regulatory framework/ reimbursement structure
      • 7.4.2.3. Competitive scenario
      • 7.4.2.4. Germany market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.4.3. France
      • 7.4.3.1. Key country dynamics
      • 7.4.3.2. Regulatory framework/ reimbursement structure
      • 7.4.3.3. Competitive scenario
      • 7.4.3.4. France market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.4.4. Italy
      • 7.4.4.1. Key country dynamics
      • 7.4.4.2. Regulatory framework/ reimbursement structure
      • 7.4.4.3. Competitive scenario
      • 7.4.4.4. Italy market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.4.5. Spain
      • 7.4.5.1. Key country dynamics
      • 7.4.5.2. Regulatory framework/ reimbursement structure
      • 7.4.5.3. Competitive scenario
      • 7.4.5.4. Spain market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.4.6. Norway
      • 7.4.6.1. Key country dynamics
      • 7.4.6.2. Regulatory framework/ reimbursement structure
      • 7.4.6.3. Competitive scenario
      • 7.4.6.4. Norway market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.4.7. Sweden
      • 7.4.7.1. Key country dynamics
      • 7.4.7.2. Regulatory framework/ reimbursement structure
      • 7.4.7.3. Competitive scenario
      • 7.4.7.4. Sweden market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.4.8. Denmark
      • 7.4.8.1. Key country dynamics
      • 7.4.8.2. Regulatory framework/ reimbursement structure
      • 7.4.8.3. Competitive scenario
      • 7.4.8.4. Denmark market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.5. Asia Pacific
    • 7.5.1. Japan
      • 7.5.1.1. Key country dynamics
      • 7.5.1.2. Regulatory framework/ reimbursement structure
      • 7.5.1.3. Competitive scenario
      • 7.5.1.4. Japan market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.5.2. China
      • 7.5.2.1. Key country dynamics
      • 7.5.2.2. Regulatory framework/ reimbursement structure
      • 7.5.2.3. Competitive scenario
      • 7.5.2.4. China market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.5.3. India
      • 7.5.3.1. Key country dynamics
      • 7.5.3.2. Regulatory framework/ reimbursement structure
      • 7.5.3.3. Competitive scenario
      • 7.5.3.4. India market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.5.4. Australia
      • 7.5.4.1. Key country dynamics
      • 7.5.4.2. Regulatory framework/ reimbursement structure
      • 7.5.4.3. Competitive scenario
      • 7.5.4.4. Australia market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.5.5. South Korea
      • 7.5.5.1. Key country dynamics
      • 7.5.5.2. Regulatory framework/ reimbursement structure
      • 7.5.5.3. Competitive scenario
      • 7.5.5.4. South Korea market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.5.6. Thailand
      • 7.5.6.1. Key country dynamics
      • 7.5.6.2. Regulatory framework/ reimbursement structure
      • 7.5.6.3. Competitive scenario
      • 7.5.6.4. Thailand market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.6. Latin America
    • 7.6.1. Brazil
      • 7.6.1.1. Key country dynamics
      • 7.6.1.2. Regulatory framework/ reimbursement structure
      • 7.6.1.3. Competitive scenario
      • 7.6.1.4. Brazil market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.6.2. Argentina
      • 7.6.2.1. Key country dynamics
      • 7.6.2.2. Regulatory framework/ reimbursement structure
      • 7.6.2.3. Competitive scenario
      • 7.6.2.4. Argentina market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.7. MEA
    • 7.7.1. South Africa
      • 7.7.1.1. Key country dynamics
      • 7.7.1.2. Regulatory framework/ reimbursement structure
      • 7.7.1.3. Competitive scenario
      • 7.7.1.4. South Africa market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.7.2. Saudi Arabia
      • 7.7.2.1. Key country dynamics
      • 7.7.2.2. Regulatory framework/ reimbursement structure
      • 7.7.2.3. Competitive scenario
      • 7.7.2.4. Saudi Arabia market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.7.3. UAE
      • 7.7.3.1. Key country dynamics
      • 7.7.3.2. Regulatory framework/ reimbursement structure
      • 7.7.3.3. Competitive scenario
      • 7.7.3.4. UAE market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.7.4. Kuwait
      • 7.7.4.1. Key country dynamics
      • 7.7.4.2. Regulatory framework/ reimbursement structure
      • 7.7.4.3. Competitive scenario
      • 7.7.4.4. Kuwait market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 8.2. Company/Competition Categorization
  • 8.3. Vendor Landscape
    • 8.3.1. List of key distributors and channel partners
    • 8.3.2. Key customers
    • 8.3.3. Key company market share analysis, 2025
    • 8.3.4. Almirall, S.A.
      • 8.3.4.1. Company overview
      • 8.3.4.2. Financial performance
      • 8.3.4.3. Product benchmarking
      • 8.3.4.4. Strategic initiatives
    • 8.3.5. Brymill Cryogenic Systems
      • 8.3.5.1. Company overview
      • 8.3.5.2. Financial performance
      • 8.3.5.3. Product benchmarking
      • 8.3.5.4. Strategic initiatives
    • 8.3.6. Sun Pharmaceutical Industries Ltd.
      • 8.3.6.1. Company overview
      • 8.3.6.2. Financial performance
      • 8.3.6.3. Product benchmarking
      • 8.3.6.4. Strategic initiatives
    • 8.3.7. Cortex Technology
      • 8.3.7.1. Company overview
      • 8.3.7.2. Financial performance
      • 8.3.7.3. Product benchmarking
      • 8.3.7.4. Strategic initiatives
    • 8.3.8. Galderma
      • 8.3.8.1. Company overview
      • 8.3.8.2. Financial performance
      • 8.3.8.3. Product benchmarking
      • 8.3.8.4. Strategic initiatives
    • 8.3.9. Ortho Dermatologics (Bausch Health Companies Inc.)
      • 8.3.9.1. Company overview
      • 8.3.9.2. Financial performance
      • 8.3.9.3. Product benchmarking
      • 8.3.9.4. Strategic initiatives
    • 8.3.10. BIOFRONTERA Inc.
      • 8.3.10.1. Company overview
      • 8.3.10.2. Financial performance
      • 8.3.10.3. Product benchmarking
      • 8.3.10.4. Strategic initiatives
    • 8.3.11. Hill Dermaceuticals, Inc
      • 8.3.11.1. Company overview
      • 8.3.11.2. Financial performance
      • 8.3.11.3. Product benchmarking
      • 8.3.11.4. Strategic initiatives
    • 8.3.12. Teva Pharmaceutical
      • 8.3.12.1. Company overview
      • 8.3.12.2. Financial performance
      • 8.3.12.3. Product benchmarking
      • 8.3.12.4. Strategic initiatives
    • 8.3.13. Viatris Inc.
      • 8.3.13.1. Company overview
      • 8.3.13.2. Financial performance
      • 8.3.13.3. Product benchmarking
      • 8.3.13.4. Strategic initiatives

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviation
  • Table 3 Global Actinic Keratosis Treatment Market, By Region, 2021 - 2033 (USD Million)
  • Table 4 Global Actinic Keratosis Treatment Market, By Therapy, 2021 - 2033 (USD Million)
  • Table 5 Global Actinic Keratosis Treatment Market, By Drug Class, 2021 - 2033 (USD Million)
  • Table 6 Global Actinic Keratosis Treatment Market, By End Use, 2021 - 2033 (USD Million)
  • Table 7 North America Actinic Keratosis Treatment Market, By Country, 2021 - 2033 (USD Million)
  • Table 8 North America Actinic Keratosis Treatment Market, By Therapy, 2021 - 2033 (USD Million)
  • Table 9 North America Actinic Keratosis Treatment Market, By Drug Class, 2021 - 2033 (USD Million)
  • Table 10 North America Actinic Keratosis Treatment Market, By End Use, 2021 - 2033 (USD Million)
  • Table 11 U.S. Actinic Keratosis Treatment Market, By Therapy, 2021 - 2033 (USD Million)
  • Table 12 U.S. Actinic Keratosis Treatment Market, By Drug Class, 2021 - 2033 (USD Million)
  • Table 13 U.S. Actinic Keratosis Treatment Market, By End Use, 2021 - 2033 (USD Million)
  • Table 14 Canada Actinic Keratosis Treatment Market, By Therapy, 2021 - 2033 (USD Million)
  • Table 15 Canada Actinic Keratosis Treatment Market, By Drug Class, 2021 - 2033 (USD Million)
  • Table 16 Canada Actinic Keratosis Treatment Market, By End Use, 2021 - 2033 (USD Million)
  • Table 17 Mexico Actinic Keratosis Treatment Market, By Therapy, 2021 - 2033 (USD Million)
  • Table 18 Mexico Actinic Keratosis Treatment Market, By Drug Class, 2021 - 2033 (USD Million)
  • Table 19 Mexico Actinic Keratosis Treatment Market, By End Use, 2021 - 2033 (USD Million)
  • Table 20 Europe Actinic Keratosis Treatment Market, By Country, 2021 - 2033 (USD Million)
  • Table 21 Europe Actinic Keratosis Treatment Market, By Therapy, 2021 - 2033 (USD Million)
  • Table 22 Europe Actinic Keratosis Treatment Market, By Drug Class, 2021 - 2033 (USD Million)
  • Table 23 Europe Actinic Keratosis Treatment Market, By End Use, 2021 - 2033 (USD Million)
  • Table 24 UK Actinic Keratosis Treatment Market, By Therapy, 2021 - 2033 (USD Million)
  • Table 25 UK Actinic Keratosis Treatment Market, By Drug Class, 2021 - 2033 (USD Million)
  • Table 26 UK Actinic Keratosis Treatment Market, By End Use, 2021 - 2033 (USD Million)
  • Table 27 Germany Actinic Keratosis Treatment Market, By Therapy, 2021 - 2033 (USD Million)
  • Table 28 Germany Actinic Keratosis Treatment Market, By Drug Class, 2021 - 2033 (USD Million)
  • Table 29 Germany Actinic Keratosis Treatment Market, By End Use, 2021 - 2033 (USD Million)
  • Table 30 Spain Actinic Keratosis Treatment Market, By Therapy, 2021 - 2033 (USD Million)
  • Table 31 Spain Actinic Keratosis Treatment Market, By Drug Class, 2021 - 2033 (USD Million)
  • Table 32 Spain Actinic Keratosis Treatment Market, By End Use, 2021 - 2033 (USD Million)
  • Table 33 France Actinic Keratosis Treatment Market, By Therapy, 2021 - 2033 (USD Million)
  • Table 34 France Actinic Keratosis Treatment Market, By Drug Class, 2021 - 2033 (USD Million)
  • Table 35 France Actinic Keratosis Treatment Market, By End Use, 2021 - 2033 (USD Million)
  • Table 36 Italy Actinic Keratosis Treatment Market, By Therapy, 2021 - 2033 (USD Million)
  • Table 37 Italy Actinic Keratosis Treatment Market, By Drug Class, 2021 - 2033 (USD Million)
  • Table 38 Italy Actinic Keratosis Treatment Market, By End Use, 2021 - 2033 (USD Million)
  • Table 39 Sweden Actinic Keratosis Treatment Market, By Therapy, 2021 - 2033 (USD Million)
  • Table 40 Sweden Actinic Keratosis Treatment Market, By Drug Class, 2021 - 2033 (USD Million)
  • Table 41 Sweden Actinic Keratosis Treatment Market, By End Use, 2021 - 2033 (USD Million)
  • Table 42 Norway Actinic Keratosis Treatment Market, By Therapy, 2021 - 2033 (USD Million)
  • Table 43 Norway Actinic Keratosis Treatment Market, By Drug Class, 2021 - 2033 (USD Million)
  • Table 44 Norway Actinic Keratosis Treatment Market, By End Use, 2021 - 2033 (USD Million)
  • Table 45 Denmark Actinic Keratosis Treatment Market, By Therapy, 2021 - 2033 (USD Million)
  • Table 46 Denmark Actinic Keratosis Treatment Market, By Drug Class, 2021 - 2033 (USD Million)
  • Table 47 Denmark Actinic Keratosis Treatment Market, By End Use, 2021 - 2033 (USD Million)
  • Table 48 Asia Pacific Actinic Keratosis Treatment Market, By Country, 2021 - 2033 (USD Million)
  • Table 49 Asia Pacific Actinic Keratosis Treatment Market, By Therapy, 2021 - 2033 (USD Million)
  • Table 50 Asia Pacific Actinic Keratosis Treatment Market, By Drug Class, 2021 - 2033 (USD Million)
  • Table 51 Asia Pacific Actinic Keratosis Treatment Market, By End Use, 2021 - 2033 (USD Million)
  • Table 52 Japan Actinic Keratosis Treatment Market, By Therapy, 2021 - 2033 (USD Million)
  • Table 53 Japan Actinic Keratosis Treatment Market, By Drug Class, 2021 - 2033 (USD Million)
  • Table 54 Japan Actinic Keratosis Treatment Market, By End Use, 2021 - 2033 (USD Million)
  • Table 55 China Actinic Keratosis Treatment Market, By Therapy, 2021 - 2033 (USD Million)
  • Table 56 China Actinic Keratosis Treatment Market, By Drug Class, 2021 - 2033 (USD Million)
  • Table 57 China Actinic Keratosis Treatment Market, By End Use, 2021 - 2033 (USD Million)
  • Table 58 India Actinic Keratosis Treatment Market, By Therapy, 2021 - 2033 (USD Million)
  • Table 59 India Actinic Keratosis Treatment Market, By Drug Class, 2021 - 2033 (USD Million)
  • Table 60 India Actinic Keratosis Treatment Market, By End Use, 2021 - 2033 (USD Million)
  • Table 61 South Korea Actinic Keratosis Treatment Market, By Therapy, 2021 - 2033 (USD Million)
  • Table 62 South Korea Actinic Keratosis Treatment Market, By Drug Class, 2021 - 2033 (USD Million)
  • Table 63 South Korea Actinic Keratosis Treatment Market, By End Use, 2021 - 2033 (USD Million)
  • Table 64 Australia Actinic Keratosis Treatment Market, By Therapy, 2021 - 2033 (USD Million)
  • Table 65 Australia Actinic Keratosis Treatment Market, By Drug Class, 2021 - 2033 (USD Million)
  • Table 66 Australia Actinic Keratosis Treatment Market, By End Use, 2021 - 2033 (USD Million)
  • Table 67 Thailand Actinic Keratosis Treatment Market, By Therapy, 2021 - 2033 (USD Million)
  • Table 68 Thailand Actinic Keratosis Treatment Market, By Drug Class, 2021 - 2033 (USD Million)
  • Table 69 Thailand Actinic Keratosis Treatment Market, By End Use, 2021 - 2033 (USD Million)
  • Table 70 Latin America Actinic Keratosis Treatment Market, By Country, 2021 - 2033 (USD Million)
  • Table 71 Latin America Actinic Keratosis Treatment Market, By Therapy, 2021 - 2033 (USD Million)
  • Table 72 Latin America Actinic Keratosis Treatment Market, By Drug Class, 2021 - 2033 (USD Million)
  • Table 73 Latin America Actinic Keratosis Treatment Market, By End Use, 2021 - 2033 (USD Million)
  • Table 74 Brazil Actinic Keratosis Treatment Market, By Therapy, 2021 - 2033 (USD Million)
  • Table 75 Brazil Actinic Keratosis Treatment Market, By Drug Class, 2021 - 2033 (USD Million)
  • Table 76 Brazil Actinic Keratosis Treatment Market, By End Use, 2021 - 2033 (USD Million)
  • Table 77 Argentina Actinic Keratosis Treatment Market, By Therapy, 2021 - 2033 (USD Million)
  • Table 78 Argentina Actinic Keratosis Treatment Market, By Drug Class, 2021 - 2033 (USD Million)
  • Table 79 Argentina Actinic Keratosis Treatment Market, By End Use, 2021 - 2033 (USD Million)
  • Table 80 MEA Actinic Keratosis Treatment Market, By Country, 2021 - 2033 (USD Million)
  • Table 81 MEA Actinic Keratosis Treatment Market, By Therapy, 2021 - 2033 (USD Million)
  • Table 82 MEA Actinic Keratosis Treatment Market, By Drug Class, 2021 - 2033 (USD Million)
  • Table 83 MEA Actinic Keratosis Treatment Market, By End Use, 2021 - 2033 (USD Million)
  • Table 84 South Africa Actinic Keratosis Treatment Market, By Therapy, 2021 - 2033 (USD Million)
  • Table 85 South Africa Actinic Keratosis Treatment Market, By Drug Class, 2021 - 2033 (USD Million)
  • Table 86 South Africa Actinic Keratosis Treatment Market, By End Use, 2021 - 2033 (USD Million)
  • Table 87 Saudi Arabia Actinic Keratosis Treatment Market, By Therapy, 2021 - 2033 (USD Million)
  • Table 88 Saudi Arabia Actinic Keratosis Treatment Market, By Drug Class, 2021 - 2033 (USD Million)
  • Table 89 Saudi Arabia Actinic Keratosis Treatment Market, By End Use, 2021 - 2033 (USD Million)
  • Table 90 UAE Actinic Keratosis Treatment Market, By Therapy, 2021 - 2033 (USD Million)
  • Table 91 UAE Actinic Keratosis Treatment Market, By Drug Class, 2021 - 2033 (USD Million)
  • Table 92 UAE Actinic Keratosis Treatment Market, By End Use, 2021 - 2033 (USD Million)
  • Table 93 Kuwait Actinic Keratosis Treatment Market, By Therapy, 2021 - 2033 (USD Million)
  • Table 94 Kuwait Actinic Keratosis Treatment Market, By Drug Class, 2021 - 2033 (USD Million)
  • Table 95 Kuwait Actinic Keratosis Treatment Market, By End Use, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Actinic Keratosis Treatment Market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 QFD modelling for market share assessment.
  • Fig. 8 Market formulation & validation
  • Fig. 9 Actinic keratosis treatment market snapshot
  • Fig. 10 Parent market outlook
  • Fig. 11 Related/ancillary market outlook.
  • Fig. 12 Penetration and growth prospect mapping
  • Fig. 13 Actinic keratosis treatment market: Therapy movement analysis
  • Fig. 14 Actinic keratosis treatment market: Therapy outlook and key takeaways
  • Fig. 15 Topical market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 16 Surgery estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 17 Photodynamic Therapy estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 18 Actinic keratosis treatment market: Drug Class movement analysis
  • Fig. 19 Actinic keratosis treatment market: Drug Class outlook and key takeaways
  • Fig. 20 Nucleoside Metabolic Inhibitor market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 21 NSAIDs estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 22 Immune Response Modifiers estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 23 Photoenhancers estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 24 Others estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 25 Actinic keratosis treatment market: End Use movement analysis
  • Fig. 26 Actinic keratosis treatment market: End Use outlook and key takeaways
  • Fig. 27 Diagnostics laboratories estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 28 Hospital/Clinics market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 29 Homecare market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 30 Others market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 31 Global actinic keratosis treatment market: Regional movement analysis
  • Fig. 32 Global actinic keratosis treatment market: Regional outlook and key takeaways
  • Fig. 33 Global actinic keratosis treatment market share and leading players
  • Fig. 34 North America, by country
  • Fig. 35 North America market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 36 U.S. key country dynamics
  • Fig. 37 U.S. market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 38 Canada key country dynamics
  • Fig. 39 Canada market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 40 Mexico key country dynamics
  • Fig. 41 Mexico market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 42 Europe market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 43 UK key country dynamics
  • Fig. 44 UK market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 45 Germany key country dynamics
  • Fig. 46 Germany market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 47 France key country dynamics
  • Fig. 48 France market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 49 Italy key country dynamics
  • Fig. 50 Italy market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 51 Spain key country dynamics
  • Fig. 52 Spain market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 53 Denmark key country dynamics
  • Fig. 54 Denmark market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 55 Sweden key country dynamics
  • Fig. 56 Sweden market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 57 Norway key country dynamics
  • Fig. 58 Norway market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 59 Asia Pacific market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 60 China key country dynamics
  • Fig. 61 China market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 62 Japan key country dynamics
  • Fig. 63 Japan market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 64 India key country dynamics
  • Fig. 65 India market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 66 Thailand key country dynamics
  • Fig. 67 Thailand market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 68 South Korea key country dynamics
  • Fig. 69 South Korea market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 70 Australia key country dynamics
  • Fig. 71 Australia market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 72 Latin America market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 73 Brazil key country dynamics
  • Fig. 74 Brazil market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 75 Argentina key country dynamics
  • Fig. 76 Argentina market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 77 Middle East and Africa market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 78 South Africa key country dynamics
  • Fig. 79 South Africa market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 80 Saudi Arabia key country dynamics
  • Fig. 81 Saudi Arabia market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 82 UAE key country dynamics
  • Fig. 83 UAE market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 84 Kuwait key country dynamics
  • Fig. 85 Kuwait market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 86 Market share of key market players- Actinic keratosis treatment market